🚀 VC round data is live in beta, check it out!
IMBiologics Valuation Multiples
Discover revenue and EBITDA valuation multiples for IMBiologics and similar public comparables like Tectonic Therapeutic, Kyverna Therapeutics, Altimmune, Zhejiang Shouxiangu and more.
IMBiologics Overview
About IMBiologics
IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. Its proprietary IM-OpDECon platform enables the design of differentiated biologics targeting autoimmune diseases and immuno-oncology. The group leverages diverse antibody modalities to tackle critical unmet medical needs beyond the reach of current therapies. Its business areas are Antibody Research & Development and Autoimmune Diseases Immuno-Oncology. The group's pipeline products are IMB-101/102, IMB-201, and IMB-402.
Founded
2020
HQ
Employees
41
Website
Sectors
Financials (FY)
EV
$511M
IMBiologics Stock Performance
IMBiologics has current market cap of $511M, and enterprise value of $511M.
IMBiologics' stock price is $34.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $511M | $511M | -5.1% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIMBiologics Valuation Multiples
IMBiologics Financial Valuation Multiples
As of April 30, 2026, IMBiologics has market cap of $511M and EV of $511M.
Equity research analysts estimate IMBiologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $511M | XXX | $511M | XXX | XXX | XXX |
| EV (current) | $511M | XXX | $511M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IMBiologics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
IMBiologics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| IMBiologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tectonic Therapeutic | XXX | XXX | XXX | XXX | XXX | XXX |
| Kyverna Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Altimmune | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Shouxiangu | XXX | XXX | XXX | XXX | XXX | XXX |
| Aquestive Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IMBiologics M&A Activity
IMBiologics acquired XXX companies to date.
Last acquisition by IMBiologics was on XXXXXXXX, XXXXX. IMBiologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by IMBiologics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIMBiologics Investment Activity
IMBiologics invested in XXX companies to date.
IMBiologics made its latest investment on XXXXXXXX, XXXXX. IMBiologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by IMBiologics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IMBiologics
| When was IMBiologics founded? | IMBiologics was founded in 2020. |
| Where is IMBiologics headquartered? | IMBiologics is headquartered in South Korea. |
| How many employees does IMBiologics have? | As of today, IMBiologics has over 41 employees. |
| Is IMBiologics publicly listed? | Yes, IMBiologics is a public company listed on Korea Exchange. |
| What is the stock symbol of IMBiologics? | IMBiologics trades under 493280 ticker. |
| When did IMBiologics go public? | IMBiologics went public in 2026. |
| Who are competitors of IMBiologics? | IMBiologics main competitors are Tectonic Therapeutic, Kyverna Therapeutics, Altimmune, Zhejiang Shouxiangu. |
| What is the current market cap of IMBiologics? | IMBiologics' current market cap is $511M. |
| Is IMBiologics profitable? | No, IMBiologics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.